Corient Private Wealth
TXG icon

Corient Private Wealth’s 10x Genomics TXG Stock Holding History

Corient Private Wealth’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.57M Sell
171,288
-39,982
-19% -$1.05M 0.01% 793
2026
Q1 		$4.37M Buy
211,270
+62,243
+42% +$1.24M 0.01% 904
2025
Q4 		$2.43M Buy
149,027
+84,197
+130% +$1.27M ﹤0.01% 1052
2025
Q3 		$758K Buy
64,830
+13,469
+26% +$176K ﹤0.01% 1564
2025
Q2 		$595K Buy
+51,361
New +$468K ﹤0.01% 1612
2024
Q2 		– Sell
-11,547
Closed -$433K – 2393
2024
Q1 		$433K Buy
+11,547
New +$507K ﹤0.01% 1707

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Corient Private Wealth's TXG Position: Q2 2026 in Review

Corient Private Wealth reduced its 10x Genomics (TXG) stake by 19% in Q2 2026, selling an estimated $1.05M and leaving 171,288 shares worth $6.57M. The position accounts for 0.01% of the portfolio, ranked #793.

Corient Private Wealth first reported a position in TXG in Q1 2024 and has held it in 6 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Corient Private Wealth held 171,288 shares of 10x Genomics worth $6.57M as of Q2 2026.
  • Corient Private Wealth sold 39,982 10x Genomics shares in Q2 2026, an estimated $1.05M.
  • 10x Genomics made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #793 holding.
  • Corient Private Wealth first reported a position in 10x Genomics in Q1 2024 and has held it in 6 quarters since.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.